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Abstract 
Objective: We try to analyse the effect of renal functions on death in CAD patients with different body compositions.
Methods: A retrospective analysis was conducted in 2989 consecutive patients with CAD confirmed by coro‑
nary angiography were enrolled and were grouped into two categories: basically preserved renal function (PRF) 
(eGFR ≥60 ml/min) and obviously reduced renal function (RRF) (eGFR <60 ml/min). The influence of renal insuffi‑
ciency on mortality of CAD was detected in every tertile of body composition, including body mass index (BMI), body 
fat (BF) and lean mass index (LMI). The end points were all‑cause mortality.
Results: The mean follow‑up time was 29.1 ± 12.5 months and death events occurred in 271 cases. The percent‑
age of patients with RRF was positively correlated with BF and inversely correlated with the LMI, but no relationship 
to BMI. The survival curves showed that the risk of death was significantly higher in the RRF patients in all subgroups 
stratified using BMI, BF, or LMI (log rank test, all p < 0.001). The COX multivariate regression analysis showed that the 
risk of death was significantly higher in the RRF patients with high BF (HR 1.95, CI 1.25–3.05) and low LMI (HR 1.82, CI 
1.19–2.79). Meanwhile, risk of death was significantly higher in RRF patients with a high BMI (HR 2.08, CI 1.22–3.55) or 
low BMI (HR 1.98, CI 1.28–3.08) but this risk was not significant in patients with a medium BMI (HR 1.12, 0.65–1.94). The 
subgroup analysis of patients with acute coronary syndrome (ACS) showed similar results.
Conclusions: For patients with CAD, renal insufficiency was positively correlated with BF, inversely correlated 
with LMI, and unrelated to BMI. The effect of renal insufficiency on the risk of death of CAD was related to body 
composition.
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Background
Obesity is becoming one of the most important global 
health problems. According to the World Health Organ-
ization (WHO) survey in 2008, approximately 35  % of 
adults over the age of 20 were overweight worldwide, 
accounting for 34 % of men and 35 % of women in this 
age group, and 10  % of men and 14  % of women were 
obese [1]. In China, the overweight population grew by 
nearly 50 % from 1992 to 2008 [2]. Studies have shown 
that obesity is associated with a range of chronic dis-
eases, such as hypertension, high cholesterol, diabetes, 
coronary artery disease (CAD), and chronic renal insuf-
ficiency [3–5]. Because obesity is a risk factor for both 
CAD and chronic renal insufficiency, patients with CAD 
are prone to obesity and renal insufficiency. A range of 
studies suggested that renal dysfunction was an inde-
pendent risk factor for death in patients with CAD [6, 
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7]. Researchers have conducted numerous studies on 
the relationship between obesity and the outcome of 
CAD but have reached different conclusions. Recently, 
researchers have proposed the theory of the “obesity 
paradox” [8, 9], and studies have shown that the obesity 
paradox applies to chronic kidney disease in addition to 
CAD [10, 11]. At present, few studies have been con-
ducted to investigate the effect of renal insufficiency on 
the outcome of coronary artery disease in patients with 
different body compositions.
In this study, we evaluated body fat with body compo-
sition-related parameters, such as the body mass index 
(BMI), body fat (BF), and lean mass index (LMI), and 
analysed the effect of renal functions on death in CAD 
patients with different body compositions.
Methods
Study population
The data source for this investigation was the West 
China Hospital CAD database. This single center data-
base prospectively includes all the CAD or high risk 
patients undergoing angiography in West China Hospi-
tal affiliated to Sichuan University. For this analysis, we 
enrolled consecutive patients with CAD from July 2008 
to January 2012 of the database. Patients with CAD 
were eligible for inclusion if they were restricted to 
participants with angiographic evidence of ≥50  % ste-
nosis in ≥1 coronary vessels. In addition to the above 
angiographic criteria, patients with acute coronary sym-
drome (ACS) were eligible for inclusion if they had the 
following criteria: (1) ischemic chest discomfort that 
increased or occurred at rest; and (2) elevated cardiac 
troponin I levels (≥0.03  μg/L) or elevated cardiac tro-
ponin T levels (≥42  ng/L); and/or (3) new or presum-
ably new electrocardiographic deviation in at least two 
contiguous leads [either pathologic Q waves (≥0.04  s 
in duration), ST segment dynamic horizontal/down-
sloping depression ≥0.05 mV, or persistent ST segment 
elevation  ≥0.1  mV in  ≥2 contiguous precordial leads 
or  ≥2 adjacent limb leads or new left bundle branch 
block (LBBB)]. The exclusion criteria included malig-
nancies, pregnancy, end stage renal disease (ESRD) 
with hemodialysis or renal transplant and severe liver or 
hematological diseases. These inclusion and exclusion 
criteria were met by 3365 continuously enrolled CAD 
patients. After excluding patients with loss of follow-up 
(n = 287) or incomplete follow-up data (n = 89), 2989 
patients were included in the data analysis. The study 
protocol was approved by the local institutional review 
boards in accordance with the Declaration of Helsinki. 
All subjects provided written informed consent before 
enrolment.
Baseline characteristics
Demographic data, medical history, cardiovascular risk 
factor, vital signs at admission, medication at discharge, 
and final diagnosis were obtained from the patients’ elec-
tronic medical records and reviewed by a trained study 
coordinator. Blood sample were collected before angiog-
raphy, and plasma biomarkers including liver and kidney 
function (including the admission SCr levels), blood glu-
cose, serum lipid, etc. were analyzed in the department 
of Laboratory Medicine, West China hospital, accred-
ited by the College of American Pathologists. Hyperten-
sion was defined as those with systolic blood pressure 
(SBP)  ≥140  mm Hg and/or diastolic blood pressure 
(DBP) ≥90 mm Hg and/or those receiving antihyperten-
sive medications. Diabetes mellitus (DM) was diagnosed 
in patients who had previously undergone dietary treat-
ment for diabetes, had received additional oral antidia-
betic or insulin medication or had a current fasting blood 
glucose level of ≥7.0  mmol/L or random blood glucose 
level ≥11.1 mmol/L. Patients received care according to 
the usual practice; treatment was not affected by partici-
pation in this study.
Body composition assessment
During hospitalization, body height and weight of the 
patients were measured by nurses using standard meth-
ods. BMI was calculated as weight (kg) divided by the 
square of height (m2). BF was estimated using the Clínica 




2 × sex) + (0.00021 × BMI2 × age), where sex is replaced 
by 0 for male and 1 for female individuals [12]. This for-
mula has been validated in a large population [13]. The 
LMI was calculated as follows: (1 − %BF) × BMI kg/m2 
[14]. As no reference value has been recommended for 
Chinese population, we divided the study patients into 
three groups according to the tertiles of sex-specific BMI, 
LMI, or BF.
Renal function assessment
SCr was finished before the angiography within first 24 h 
after admission and assessed by a nonkinetic alkaline 
picrate (Jaffe) method. The Modification of Diet in Renal 
Disease (MDRD) equation was used to estimate glomer-
ular filtration rate (eGFR) in milliliters per minute per 
1.73 m2 [15]. Patients were divided into two eGFR groups: 
the basically preserved renal function (PRF) group [nor-
mal or mildly impaired renal function corresponding to 
strata used to define chronic kidney disease (CKD) stages 
[16], eGFR ≥60 ml/min] and the obviously reduced renal 
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function (RRF) group (moderately or severely impaired 
renal function, eGFR <60 ml/min).
Follow‑up and end points
The follow-up period ended on January 2013. Follow-up 
information was collected through contact with patients’ 
physicians, patients or their family. All data were corrob-
orated with the hospital records. The primary end points 
in this study were all-cause mortality and the secondary 
end points were cardiovascular death, as documented in 
the database. Death was considered cardiac when it was 
caused by acute MI, significant arrhythmias, or refractory 
heart failure. Sudden unexpected death occurring with-
out another explanation was included as cardiovascular 
death.
Statistical analyses
We conducted the post hoc analysis on a retrospective 
basis. Baseline demographics and clinical characteris-
tics were compared among patients categorized by the 
admission eGFR levels in two groups. Continuous vari-
ables are expressed as the mean  ±  standard deviation 
(SD), and categorical variables are reported as counts and 
percentages. Analysis of t test and Chi squared tests were 
used to test for differences between groups for continu-
ous and categorical variables, respectively. The compari-
sons of the distribution of eGFR <60 min/ml across the 
body composition tertiles were performed in Chi squared 
tests. To determine the association between renal func-
tion and all-cause mortality, Kaplan–Meier curves by 
eGFR levels were constructed in different body compo-
sition strata and examined using the log-rank test for 
comparison, respectively. Hazard ratios (HRs) and 95  % 
confidence intervals (CIs) were calculated based on Cox 
proportional hazards regression models, which was used 
to investigate the independent effect of renal function 
on the outcome events. Adjustments were made for the 
possible confounding effects of age, sex, medical his-
tory (pre-hypertension and pre-diabetes mellitus), heart 
function (Killip level), severity of CAD (left main artery 
and three vessel diseases), discharge medications [sta-
tin, angiotensin-converting enzyme (ACE) inhibitors or 
angiotensin-receptor blockers (ARBs) and beta-receptor 
blockers]. Two-sided p values of less than 0.05 indicated 
statistical significance. All analyses were performed with 
SPSS software (version 19.0).
Results
A total of 2989 patients with coronary artery disease 
were included in this study. The patients were aged 
64.5 ±  10.6  years on average, and 20.5  % were women. 
SCr was determined within 24  h after admission. The 
mean estimated glomerular filtration rate (eGFR) was 
79.5  ±  22.9  ml/min, with an eGFR  <60  ml/min in 506 
patients (16.9 %). The baseline data are shown in Table 1. 
Significant differences were observed in the clinical char-
acteristics between groups, with more severe renal insuf-
ficiency associated with an older age, female gender, and 
comorbidities such as hypertension, diabetes, cardiac 
dysfunction, and complex CAD.
Figure  1 shows the relationship between renal insuffi-
ciency and body composition. For patients with CAD, the 
percentage of patients with RRF was positively correlated 
with BF and inversely correlated with the LMI; no signifi-
cant relationship was observed between the BMI and the 
percentage of patients with renal insufficiency.
All the patients were followed up for an average of 
29.1  ±  12.5  months, during which 271 patients died 
(mortality rate: 9.1  %), including 150 who died of car-
diovascular events (cardiac mortality rate: 5.0  %). The 
survival curves showed that the risk of death was signifi-
cantly higher in the RRF patients in all subgroups strati-
fied using BMI, BF, or LMI (log rank test, all p < 0.001; 
Fig. 2).
The COX multivariate regression analysis showed 
that the risk of death was significantly higher in the 
RRF patients with high BF (BF tertile 3) (HR 1.95, CI 
1.25–3.05) and low LMI (LMI tertile 1) (HR 1.82, CI 
1.19–2.79), whereas the risk of RRF for death was not 
significant in patients with low BF (BF tertile 1) (HR 
1.64 0.92–2.93) and high LMI (LMI tertile 3) (HR 1.71, 
CI 0.91–3.20) after multivariable correction (Table 2). In 
contrast, RRF was a risk factor for death in patients with 
a high BMI (BMI tertile 3) (HR 2.08, CI 1.22–3.55) or 
low BMI (BMI tertile 1) (HR 1.98, CI 1.28–3.08) but this 
risk was not significant in patients with a medium BMI 
(BMI tertile 2) (HR 1.12, 0.65–1.94). The subgroup analy-
sis of patients with ACS showed similar results (Table 2). 
Analysis of cardiac death (Table 3) showed that RRF was 
a more significant risk factor for death in patients with 
high BF (HR 1.90, CI 1.00–3.62) and low LMI (HR 2.46, 
CI 1.39–4.37), which was consistent with the findings of 
the analysis of all-cause death; however, the risk of RRF 
for cardiac death was only significant in patients with a 
low BMI but not those with a high or medium BMI. For 
ACS patients, the risk of RRF for cardiac death was only 
in patients with low LMI and was unrelated to cardiac 
death in all of the BMI and BF subgroups. This result 
might be related to the low number of cardiac death 
cases, which could have resulted in insufficient statistical 
power in the ACS subgroup.
Discussion
The study showed that renal insufficiency was posi-
tively correlated with BF, inversely correlated with LMI, 
and unrelated to BMI for patients with CAD. Moreover, 
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the effect of renal insufficiency on the risk of death of 
CAD was related to body composition. The relationship 
between renal insufficiency and risk of mortality was 
more significant in CAD patients with higher BF and 
lower LMI, and with lower or higher BMI.
Some previous observational studies showed that 
obesity was a risk factor for chronic renal insufficiency 
[17–19], but other studies reached different conclusions 
[20–22]. Some researchers believed that the discrep-
ancy arose because most of the previous studies used 
BMI as an indicator of obesity; however, BMI is not an 
accurate measure of obesity because it does not distin-
guish between body lean mass and body fat mass and 
body fat mass may play a major role in renal damage. 
Thus, recently researchers have proposed using BF and 
LMI to measure obesity [14, 23]. This study showed that 
renal insufficiency in patients with CAD was unrelated to 
BMI but was positively related to BF and inversely related 
to LMI, suggesting that BF and LMI were more effec-
tive measures than BMI when analysing the relationship 
between obesity and renal insufficiency. However, few 
studies have been conducted on this topic, and further 
exploration is warranted. The mechanism by which obe-
sity causes renal damage is unknown. Possible mecha-
nisms may be related to obesity-induced haemodynamic 
changes, a higher glomerular filtration burden, hormo-
nal effects, and the activation of the renin-angiotensin-
aldosterone-system (RAAS). Moreover, obese patients 
are prone to diabetes and hypertension, which indirectly 
cause renal damage [24, 25].
Renal insufficiency is an important risk factor for 
death and cardiovascular events in patients with CAD 
[6, 7, 26]. Furthermore, obese patients are susceptible to 
a range of cardiovascular risk factors, including hyper-
tension, blood sugar disorders, dyslipidemia, and active 
inflammation [4]. Thus, cardiovascular risk factors may 
superimpose on one another in CAD patients compli-
cated with obesity and renal insufficiency simultane-
ously. Obesity, especially the visceral adiposity would 
increase the risk of cardiovascular events and death in 
patients with renal insufficiency. The previous study 
found that visceral adiposity index is an optimal method 
to measure visceral adiposity to assess long-term CV 
outcomes and all-cause mortality in prevalent hemodi-
alysis patients [27]. Epicardial adipose tissue accumula-
tion in patients with CKD stage 3–5 increases the risk 
of CV events independent of general adiposity [28]. Vis-
ceral adiposity is associated with adverse cardiovascu-
lar outcomes for patients with CKD, while sarcopenia 
is common among patients with ESRD and is associ-
ated with higher mortality [29]. Considering the close 
relationship between obesity and renal insufficiency, 
accordingly, we have reason to speculate that renal 
Table 1 Baseline characteristics of the study population
Data are expressed as mean ± SD or counts and percentages, as appropriate
BMI body mass index; BF body fat; LMI lean mass index; eGFR estimated 
glomerular filtration rate; ACS acute coronary syndrome; UA unstable angina; 
CAD coronary artery disease; ACE angiotensin-converting enzyme; ARBs 
angiotensin-receptor blockers
Characteristics eGFR p value
Total <60 mL/min ≥60 mL/min
No. of patients n = 2989 n = 506 n = 2483
Age, years 64.5 ± 10.6 70.4 ± 8.0 63.3 ± 10.7 <0.001
Gender, female, 
n (%)
614 (20.5) 162 (32.0) 452 (18.2) <0.001
Body composition parameters
 BMI, kg/m2 24.2 ± 2.9 24.1 ± 2.8 24.2 ± 2.9 0.477
 BF, % 28.1 ± 6.2 30.2 ± 6.6 27.7 ± 6.0 <0.001




902 (30.2) 151 (29.8) 751 (30.2) 0.857
 Pre‑hyperten‑
sion, n (%)
1628 (54.5) 352 (69.6) 1276 (51.4) <0.001
 Pre‑diabetes 
mellitus, n (%)
653 (21.8) 154 (30.4) 499 (20.1) <0.001
At admission
 Systolic blood 
pressure, mm 
Hg
130.3 ± 21.2 132.0 ± 24.1 129.9 ± 20.6 0.059
 Diastolic blood 
pressure, mm 
Hg
76.3 ± 12.5 74.2 ± 13.4 76.7 ± 12.3 <0.001
 Heart rate, 
beats/min
74.1 ± 13.9 76.3 ± 16.1 73.6 ± 13.4 0.001
 Killip classifica‑
tion ≥ II, n (%)




79.5 ± 22.9 45.9 ± 12.4 86.3 ± 18.0 <0.001
 Blood glu‑
cose, mmol/L
6.9 ± 3.1 7.7 ± 4.1 6.8 ± 2.8 <0.001
 Total choles‑
terol, mmol/L
4.1 ± 1.1 4.0 ± 1.1 4.1 ± 1.1 0.222
Diagnosis
 ACS, n (%) 2163 (72.4) 382 (75.5) 1781 (71.7) 0.084
 UA, n (%) 1533 (51.3) 257 (50.8) 1276 (51.4) 0.806
Severity of CAD
 Left main artery, 
n (%)
282 (9.4) 54 (10.7) 228 (9.2) 0.296
 Three vessel dis‑
eases, n (%)
758 (25.4) 176 (34.8) 582 (23.4) <0.001
Discharge medication
 Aspirin, n (%) 2760 (92.3) 432 (85.4) 2328 (93.8) <0.001
 Clopidogrel, 
n (%)
2670 (89.3) 428 (84.6) 2242 (90.3) <0.001
 Statin, n (%) 2678 (89.6) 432 (85.4) 2246 (90.5) 0.001
 ACE inhibitors or 
ARBs, n (%)
1702 (56.9) 290 (57.3) 1412 (56.9) 0.854
 Beta‑receptor 
blockers, n (%)
1981 (66.3) 301 (59.5) 1680 (67.7) <0.001
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function may perform different influence on the out-
come of patients with different body compositions. Our 
study showed that renal insufficiency was a more sig-
nificant risk factor for all-cause death and cardiac death 
in CAD patients with a higher body fat content (i.e., 
high BF and low LMI), suggesting that the fat mass may 
have a synergistic effect with renal insufficiency, thereby 
increasing the risk of death in CAD patients with renal 
insufficiency and obesity. How obesity causes cardiovas-
cular disease is not entirely clear, but researchers believe 
that fat cells play an important role in this process as 
an endocrine organ [30]. Obese patients have a higher 
inflammation level and leptin resistance, which increase 
the risk of cardiovascular events [31, 32]. Moreover, 
obesity induces haemodynamic changes, increases the 
cardiac burden, induces cardiac remodelling, and affects 
cardiac functions [33].
Previous study found a U-shaped association of body 
mass index with inflammation and atherosclerosis in 
hemodialysis patients [34]. Interestingly, our study 
showed that renal insufficiency increased the risk of 
death of CAD in patients with a low BMI or high BMI 
but not in patients with a medium BMI (after multivari-
ate correction), indirectly demonstrating that the BMI 
reflects the patient’s physical and nutritional status but 
not necessarily the body fat content. Patients with a high 
BMI are more likely to be obese, and thus, renal insuf-
ficiency may increase the risk of death in these patients, 
whereas patients with a low BMI are likely to have both 
a low fat body mass and low lean body mass (poor nutri-
tional status); thus, renal insufficiency may more likely 
increase the risk of death in these patients. A previ-
ous cross-sectional study investigated the BMI and BF% 
(measured with air displacement plethysmography) in 
coronary artery disease (CAD) patients and showed that 
BMI failed to distinguish the fat mass from lean mass 
[35]. Our results indirectly support this opinion. For 
studies of the outcome of CAD, BF% and LMI may be 
more effective indicators than BMI for the risk of death.
This study has certain limitations. First, this study was 
a single-centre observational study. Despite multivariate 
correction, it was difficult to avoid all the confounding 
effect of (residual) selection bias absolutely. Moreover, 
in this single-centre study, all of the enrolled subjects 
were Chinese; thus, the potential for racial variation is 
unknown. Second, because the sample size of ACS sub-
group was small relatively, the statistical power might 
have been inadequate in the analysis of cardiac death; 
thus, caution is needed when considering these results. 
In addition, the sample size of hemodialysis is small and 
we could hardly perform the analysis for this special sub-
group. Considering the heterogeneity of patients with 
hemodialysis compared with patients without hemodi-
alysis, we excluded the patients with hemodialysis in this 
study. Third, serum creatinine was collected only once 
after admission, and thus, measurement error could not 
be rule out definitely. Meanwhile, the serum creatinine 
levels might substantially change in some patients dur-
ing hospitalization and the follow-up treatment after dis-
charge. However, it is not always possible to repeat the 
serum creatinine test in an observational study, which is 
an inherent limitation of real world studies. Finally, this 
Fig. 1 The proportion of patients with eGFR <60 min/ml across the BMI (a), BF (b) and LMI (c) tertiles. eGFR estimated glomerular filtration rate; BMI 
body mass index; BF body fat; LMI lean mass index
Page 6 of 10Peng et al. Cardiovasc Diabetol  (2016) 15:106 
study was conducted in patients with CAD, and thus, it 
is unknown whether the results can be applied to renal 
insufficient patients without CAD.
Conclusions
For patients with CAD, renal insufficiency was positively 
correlated with BF, inversely correlated with LMI, and 
unrelated to BMI. The effect of renal insufficiency on the 
Fig. 2 Kaplan‑Meier plots according to the eGFR levels (min/ml) across the BMI, BF and LMI tertiles. eGFR estimated glomerular filtration rate; BMI 
body mass index; BF body fat; LMI lean mass index
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risk of death of CAD was related to body composition. 
Renal insufficiency was a more significant risk factor in 
CAD patients with higher BF and lower LMI, and with 
lower or higher BMI.
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